Plain-English translation of NCT06211166 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
After you receive a stem cell transplant for leukemia or a related blood disorder, doctors need to monitor whether any cancer cells remain in your body. This study is testing a newer blood test method called digital polymerase chain reaction to see if it's better than traditional methods at detecting these remaining cancer cells and predicting whether your cancer might come back.
Current methods for detecting remaining cancer cells after transplant have limitations. Researchers believe the newer blood test method may be more sensitive and accurate, which could help doctors catch early warning signs of relapse and adjust your treatment sooner.
You likely qualify if…
You likely don't qualify if…
You would continue to receive regular follow-up care after your stem cell transplant, and your doctors would monitor you using both the new blood test method and standard methods to detect remaining cancer cells. The study involves comparing the results of these different testing approaches over time to see which method is most helpful at predicting relapse. You would likely have blood draws at regular clinic visits, with no additional procedures beyond what you're already receiving as part of your transplant care.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
Peking University People's Hospital
Enrollment target
~300 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Meng Lv, M.D,Ph.D
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.